This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Other lower respiratory disease
  • /
  • American Thoracic Society. Idiopathic pulmonary fi...

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Read time: 1 mins
Published:1st Feb 2000
Author: [No authors listed]
Availability: Free full text
Ref.:Am J Respir Crit Care Med. 2000;161(2 Pt 1):646-64.

Many acute and chronic lung disorders with variable degrees of pulmonary inflammation and fibrosis are collectively referred to as interstitial lung diseases (ILDs) or diffuse parenchymal lung diseases. Idiopathic pulmonary fibrosis (or cryptogenic fibrosing alveolitis) (IPF or CFA) is one of several idiopathic interstitial pneumonias. IPF is now recognized as a distinct clinical disorder. Despite major accomplishments in our understanding of the pathogenesis of lung fibrosis (1), the diagnosis and management of patients with IPF continues to pose significant challenges (2-4).

This is an international consensus statement defining the diagnosis, evaluation, and management of patients with IPF that has been produced as a collaborative effort from the American Thoracic Society (ATS), European Respiratory Society (ERS), and the American College of Chest Physicians (ACCP). The purpose of this consensus statement is to provide assistance to clinicians in the diagnosis and management of idiopathic pulmonary fibrosis (IPF). The targeted providers are pulmonary subspecialists.

Access full article